FC01.1B

Scan the QR code.
The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.

This material is distributed for scientific purposes on J&J Medical Connect and is not for promotional use

Exploring Super Responders Who Remained Treatment-free for More Than 3 Years After Guselkumab Withdrawal: Insights From the Phase 3b GUIDE Trial in Psoriasis

Knut Schäkel[1], Matthias Hoffmann[2], Michael Sebastian[3], Margrit Simon[4], Maurizio Podda[5], Peter Radny[6], Matthias Hahn[7], Jan C Simon[8], Peter Weisenseel[9], Khusru Asadullah[10, 11], Andreas Pinter[12], Carle Paul[13], Friedemann Taut[14], Judita Makuc[15], Nenja Krüger[15], Nikolas Spindler[15], Kilian Eyerich[16]

[1]Department of Dermatology, and Interdisciplinary Center for Inflammatory Diseases, Heidelberg University Hospital, Heidelberg, Germany, [2]Dermatological Practice Dr. med. Matthias Hoffmann, Witten, Germany, [3]Dermatological Practice Dr. med. Michael Sebastian, Mahlow, Germany, [4]Dermatology Practice and Clinical Study Center Dr. med. Margrit Simon, Berlin, Germany, [5]Department of Dermatology, Medical Center Klinikum Darmstadt, Teaching Hospital Goethe-University Frankfurt, Darmstadt, Germany, [6]Derma-Study-Center-FN GmbH Dr. med. Peter Radny, Friedrichshafen, Germany, [7]Department of Dermatology, University Medical Center, Eberhard Karls University Tübingen, Tübingen, Germany, [8]Department of Dermatology, Venerology and Allergology, Leipzig University Medical Center, Leipzig, Germany, [9]Dermatologikum Hamburg, Hamburg, Germany, [10]Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin, Berlin, Germany, [11]Dermatology Potsdam MVZ, Potsdam, Germany, [12]University Hospital Frankfurt am Main, Frankfurt, Germany, [13]Toulouse University, Toulouse, France, [14]Taut Science and Service GmbH, Konstanz, Germany, [15]Johnson & Johnson, Neuss, Germany, [16]Department of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg, Germany

This presentation was sponsored by Johnson & Johnson.

Presented by Knut Schäkel at EADV; September 17-20, 2025; Paris, France

Conflicts of Interest

KS: Advisory board/consultant/speaker/clinical trials/honoraria/grants: AbbVie, Apogee, Alumis, Amgen, Almirall, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celldex Therapeutics, Chugai, Galderma, Incyte, Johnson & Johnson, Leo Pharma, Eli Lilly, Merck Sharp & Dohme Corp., Morphosys, Nektar Therapeutics, Novartis, Regeneron, Sanofi, Smerud, and UCB.

MHo: Advisory board/consultant/speaker/clinical trials/honoraria/grants: AbbVie, Almirall, Biofrontera, Bristol Myers Squibb, Dermapharm, Dermasence, Forward, Galderma, Incyte, Johnson & Johnson, Kiniksa, Leo Pharma, Eli Lilly, L'Oréal, MSD, Nektar Therapeutics, Novartis, Pierre Fabre, Pfizer, Sanofi, Schering-Plough, Smerud Medical Research, Stallergenes Greer, Viatris, and UCB.

MSe: Cooperation with: AbbVie, Affibody, Allergan, Almirall, Alumis, Amgen, Apogee, AstraZeneca, August Wolff, Boehringer Ingelheim, Bristol Myers Squibb, Dermapharm, Dermira, Incyte, Ipsen, Johnson & Johnson, Leo Pharma, Eli Lilly, MedImmune, Menlo Therapeutics, Merz Pharma, Moonlake, MSD, Mundipharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Takeda, UCB, and Zuellig Pharma.

MSi: None to declare

MP: COIs could not be confirmed as Prof. Podda passed away during the preparation of the presentation.

PR: Advisory board/consultant/speaker/clinical trials/honoraria/grants: Abbvie, Almirall, Amgen, Beiersdorf, Biofrontera, Biogen, Bristol Myers Squibb, Cutanea Life Science, Dermapharm AG, Dermira, Eli Lilly, Foamix, Forward-Pharma, Galderma, Galenpharma, Hermall, Incyte, Inovio, Infectopharm, Johnson & Johnson, Leo Pharma, Leti, Medac, Medimmune, Moberg Derma AB, MSD, Novartis, Pfizer, Pharmaceuticals, Regeneron/Sanofi, Smerud, UCB, and VBL Therapeutics.

MHa: Advisory board/investigator/grants: AbbVie, Almirall, Alumis, Amgen, Argenex, Apogee Therapeutics, Bristol Myers Squibb, Boehringer Ingelheim, Celldex, Chugai, Concert, Immunovant, Incyte, Galapagos, Johnson & Johnson, Leo Pharma, Eli Lilly, Novartis, Pfizer, Sanofi, Takeda, Topas, and UCB.

JCS: Advisory boards/speaker: Almirall, Bristol-Myers Squibb, Johnson & Johnson, Leo Pharma, Eli Lilly, MSD, Novartis, Pfizer, and Pierre Fabre.

PW: Advisory board/speaker/clinical trials/grants: AbbVie, Almirall, Biogen, Bristol Myers Squibb, Celgene, Eli Lilly, Johnson & Johnson, Leo Pharma, Medac, Novartis,Pfizer, and UCB Pharma.

KA: Advisory board/speaker/clinical trials/grants: AbbVie, Akribes, Almirall, Antabio, Bayer, DEKA Biosciences, Emeriti Pharma, Galderma, Incyte, Johnson & Johnson, LEO Pharma, L'Oréal, Novartis, Pierre Fabre, Sanofi Genzyme, and UCB.

AP: Advisor/speaker/grants/clinical trials: AbbVie, Almirall Hermal, Amgen, Biogen Idec, BioNTech, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Galderma, GSK, Hexal, Johnson & Johnson, Klinge Pharma, Leo Pharma, MC2, Medac, Merch Serono, Mitsubishi, MSD, Noavartis, Pascoe, Pfizer, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi Genzyme, Schering-Plough, Tigercat Pharma, UCB, and Zuellig Pharma.

CP: Advisory board/speaker/clinical trials/grants: AbbVie, Almirall, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Galderma, Eli Lilly, Iqvia, Johnson & Johnson, Merck, Mylan, Novartis, Pfizer, Sanofi, and UCB.

FT: Owns Taut Science & Service GmbH, a consultancy specialized in clinical research and medical affairs, receiving consultancy fees from Johnson & Johnson.

JM, NK, NS: Employee: Johnson & Johnson; Shareholder: Johnson & Johnson.

KE: Speaker/advisory board: AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Hexal, Johnson & Johnson, Leo Pharma, Novartis, Pfizer, Sanofi, Sitryx, and UCB. Co-founder/shareholder: Dermagnostix and Dermagnostix R&D.

This material is distributed for scientific purposes on Med Medical Connect, and is not for promotional use

Background

Psoriasis (PSO)

- Chronic, immune-driven, relapsing-remitting inflammatory skin disease[1]
- Primarily driven by dysregulation of the IL-23/IL-17 axis[2]

Guselkumab (GUS)

- Fully human, mAb that selectively inhibits IL-23 by targeting its p19 subunit
- Proven efficacy in patients with moderate-to-severe plaque PSO[3–6]
- Approved to treat moderate-to-severe PSO, active psoriatic arthritis and moderately-to-severely active ulcerative colitis and Crohn's disease[7]

GUIDE study

- Prospective Phase 3b RCT investigating early intervention with GUS for disease modification in patients with PSO[7]

This material is distributed for scientific purposes only by J&J Medical Connect, and is not for promotional use

1. Siemińska I et al. *Clinic Rev Allerg Immunol* 2024; 66(2):164–191. **2.** Menter A et al. *Dermatol Ther (Heidelb)* 2021;11(2):385-400. **3.** Blauvelt A et al. *J Am Acad Dermatol* 2017;76:405–17. **4.** Reich K et al. *J Am Acad Dermatol* 2017;76:418–31. **5.** Langley RG et al. *Br J Dermatol* 2018;178:114–23. **6.** Reich K et al. *Lancet* 2019;394:831–9. **7.** Tremfya Product Information: https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf. **IL**=interleukin, **mAb**=monoclonal antibody, **RCT**=randomized controlled trial

Methods

This material is distributed for scientific purposes on J&J Medical Connect, and is not for promotional use

GUIDE study design – Parts 1 and 2

Key inclusion criteria [NCT03818035]

- Adults with moderate-to-severe PSO
- ~40% with PSO for ≤2 years



GUIDE Part 1: Identification of SRes[1]

- Early treatment with GUS (SDD; ≤2 years from symptom onset) increased likelihood of becoming an SRe[2]

GUIDE Part 2: Disease control with an extended dosing interval for SRes[1]

- Primary endpoint was met:
  - Non-inferiority of GUS dosed q16w vs q8w in SRes for maintenance of disease control (PASI <3) at W68 was demonstrated[3]

Material is distributed for scientific purposes on J&J Medical Connect and not for promotional use

1. Eyerich K *et al. BMJ Open* 2021;11:e049822. **2.** Schäkel K *et al. J Eur Acad Dermatol Venereol* 2023;37:2016–27; **3.** Eyerich K *et al. JAMA Dermatol* 2024;e242463. [a]Blinded treatment. **GUS**=guselkumab, **Non-SRe**=non super responder, **PASI**=Psoriasis Area and Severity Index, **PSO**=psoriasis, **q8w**=every 8 weeks, **q16w**=every 16 weeks, **R**=retreatment, **Rand**=randomization, **SDD**=short disease duration, **SRe**=super responder, **W**=week.

GUIDE study design – Parts 1, 2 and 3

Key inclusion criteria [NCT03818035]

- Adults with moderate-to-severe PSO
- ~40% with PSO for ≤2 years



This material is distributed for scientific purposes on J&J Medical Connect and is not for promotional use

[a]Blinded treatment. **GUS**=guselkumab, **Non-SRe**=non super responder, **PASI**=Psoriasis Area and Severity Index, **PSO**=psoriasis, **q8w**=every 8 weeks, **q16w**=every 16 weeks, **R**=retreatment, **Rand**=randomization, **SRe**=super responder, **W**=week.

GUIDE study design – Part 3

Phase 3b randomized, placebo-controlled, double-blind, parallel-group, multicentre study of adults with moderate-to-severe plaque PSO[1]

Objectives of GUIDE Part 3 W220 analysis

- To determine how long patients can sustain disease control after GUS withdrawal
- To identify SRes who maintained response for >3 years after the last GUS dose
- To assess if disease duration has an impact on remaining treatment-free



This material is distributed for scientific purposes on J&J Medical Connect and is not for promotional use

1. Eyerich K *et al. BMJ Open* 2021;11:e049822. **GUS**=guselkumab, **PASI**=Psoriasis Area and Severity Index, **PSO**=psoriasis, **q8w**=every 8 weeks, **q16w**=every 16 weeks, **R**=retreatment, **SRe**=super responder, **W**=week.

Results

This material is distributed for scientific purposes on J&J Medical Connect, and is not for promotional use

SRes remaining treatment-free through 3 years tended to have shorter disease duration and received no prior systemic therapies

Baseline Characteristics of SRes Entering GUS Withdrawal in GUIDE Part 3	SRes remaining treatment-free until W220 (N = 13)	SRes initiating re-treatment prior to W220 (N = 260)
Demographics		
Mean age, years (SD)	42.4 (12.4)	39.6 (14.1)
Male, n (%)	9 (69.2)	178 (68.5)
Female, n (%)	4 (30.8)	82 (31.5)
Mean BMI, kg/m^2 (SD)	26.1 (4.7)	27.0 (5.2)
Disease Characteristics		
Mean PSO duration, years (SD)	2.0 (4.7)	10.6 (12.8)
LDD (>2 years), n (%)	1 (7.7)	134 (51.5)
SDD (≤2 years), n (%)	12 (92.3)	126 (48.5)
USDD (<15 months), n (%)	11 (84.6)	56 (21.5)
ISDD (≥15–≤24 months), n (%)	1 (7.7)	70 (26.9)
Mean BSA with PSO, % (SD)	19.1 (11.6)	25.2 (15.4)
Mean PASI (0-72) (SD)	14.6 (3.6)	18.9 (7.5)
Hierarchical Prior PSO Medication[a]		
Topical therapy, n (%)	9 (69.2)	85 (32.7)
Phototherapy[b], n (%)	2 (15.4)	50 (19.2)
Non-biologic systemic therapy[c] , n (%)	0 (0)	100 (38.5)
Biologic therapy[d], n (%)	0 (0)	21 (8.1)
GUS dosing in part 2: q8w/q16w, %	53.8/46.2	48.9/51.2

[a]Counts per most advanced therapy regimen. [b]PUVA, UVB, UVA or photosole, [c]Methotrexate, cyclosporine, fumaric acid esters, acitretin, apremilast, tofacitinib, oral steroids, and other. [d]Infliximab, etanercept, adalimumab, efalizumab, ustekinumab, secukinumab, ixekizumab, brodalumab, certolizumab, and other. **BMI**=body mass index, **BSA**=body surface area, **GUS**=guselkumab, **ISDD**=intermediate-short disease duration, **LDD**=long disease duration, **PASI**=Psoriasis Area and Severity Index, **PSO**=psoriasis, **PUVA**=psoralen + ultraviolet A, **q8w**=every 8 weeks; **q16w**=every 16 weeks, **SD**=standard deviation, **SDD**=short disease duration, **SRe**=super responder, **USDD**=ultra-short disease duration, **UV**=ultraviolet, **W**=week.

This material is distributed for scientific purposes on J&J Medical Connect, and is not for promotional use

Overall, 11 of 13 SRes remaining treatment-free through 3 years after withdrawing from GUS had <15 months PSO duration (USDD)

Baseline Characteristics of SRes Remaining Treatment-free in GUIDE Part 3

		Patient												
		1	2	3	4	5	6	7	8	9	10	11	12	13
Demographics														
	Age, years	37	19	50	51	26	55	41	34	43	58	58	31	48
	Sex	Male	Male	Female	Male	Male	Female	Male	Male	Male	Male	Male	Female	Female
	BMI, kg/m^2	29.1	20.5	26.5	30.3	22.2	22.6	22.6	30	24.8	36.2	30.1	20.9	24.1
Disease Characteristics														
	PSO duration, yrs	17.6	1.4	1.2	0.3	0.8	1.2	1.1	0.4	0.8	0.2	0.4	0.5	0.7
	PSO duration category	LDD	ISDD	USDD										
	PASI (0-72)	12.8	13.8	13	18.6	11.8	16.2	13.8	22.4	12.6	12.8	19.6	11.5	10.6
	DLQI (0-30)	22	21	28	21	15	12	27	24	13	24	23	11	12
PSO Medication Use														
	PSO therapy	Topical + PUVA	Topical + UVB	Only topical										No therapy
	Biologic therapy	Biologic naïve												
GUS dosing in Part 2		q16w	q8w									q16w		

This material is distributed for scientific purposes only J&J Medical Connect, and is not for promotional use

BMI=body mass index, **DLQI**=Dermatology Life Quality Index, **GUS**=guselkumab, **ISDD**=intermediate-short disease duration, **LDD**=long disease duration, **PASI**=Psoriasis Area and Severity Index, **PSO**=psoriasis, **PUVA**=psoralen + ultraviolet A, **q8w**=every 8 weeks; **q16w**=every 16 weeks, **SRe**=super responder, **USDD**=ultra-short disease duration, **UV**=ultraviolet, **W**=week.

SRes with USDD (<15 months) had the highest probability of remaining treatment-free through 3 years after GUS withdrawal



Number at risk

USDD	67	67	67	61	48	34	23	21	18	18	16	13	12	11
ISDD	71	71	65	48	28	16	12	7	5	4	3	2	2	1
LDD	135	135	120	70	39	24	13	8	5	5	3	3	2	2[a]

Disease duration	Months
USDD	<15
ISDD	≥15 and ≤24
LDD	>24

Median treatment-free duration

Overall population: **302** days

USDD patients: **456** days

ISDD patients: **291** days

LDD patients: **259** days

USDD vs **ISDD**: **↑ 165 days (+57%)**

USDD vs **LDD**: **↑ 197 days (+76%)**

***p* values are nominal.**

13 SRes remained treatment-free for >3 years following GUS withdrawal

This material is distributed for scientific purposes of J&J Medical Connect, and is not for promotional use

Loss of maintenance of response was defined as PASI >5, at which point treatment was re-initiated. [a]One patient with maintenance of disease control for >3 years experienced loss of disease control at W212 prior to W220.**CI**=confidence interval; **GUS**=guselkumab, **HR**=hazard ratio, **ISDD**=intermediate-short disease duration, **LDD**=long disease duration, **PASI**=Psoriasis Area and Severity Index, **SRe**=super responder, **USDD**=ultra-short disease duration.

Similar results were observed in the subgroup of SRes withdrawing from GUS q8w dosing



Number at risk

USDD	28	28	28	22	19	13	10	10	8	8	8	8	7	6
ISDD	39	39	35	27	18	9	8	4	3	3	2	2	2	1
LDD	69	69	62	32	18	12	6	4	3	3	1	1	0	0

Disease duration	Months
USDD	<15
ISDD	≥15 and ≤24
LDD	>24

Median treatment-free duration

USDD patients: **456** days
ISDD patients: 344 days
LDD patients: 233 days

USDD vs ISDD: **↑ 112 days (+33%)**
USDD vs LDD: **↑ 223 days (+96%)**

***p* values are nominal.**

CI=confidence interval; **GUS**=guselkumab, **HR**=hazard ratio; **ISDD**=intermediate-short disease duration, **LDD**=long disease duration, **q8w**=every 8 weeks, **SRe**=super responder, **USDD**=ultra-short disease duration.

This material is distributed for scientific purposes on J&J Medical Connect, and is not for promotional use

Loss of maintenance of response was defined as PASI >5, at which point treatment was re-initiated. **CI**=confidence interval; **GUS**=guselkumab, **HR**=hazard ratio, **ISDD**=intermediate-short disease duration, **LDD**=long disease duration, **PASI**=Psoriasis Area and Severity Index, **SRe**=super responder, **USDD**=ultra-short disease duration.

The 13 SRes who remained treatment-free for >3 years after withdrawing from GUS had high PASI responses at W220[a]



At W220:

- All SRes achieved disease control (PASI <3)
- 10 of 13 SRes showed complete skin clearance (PASI = 0)

This material is distributed for scientific purposes on J&J Medical Connect, and is not for promotional use

[a]W220 corresponds to >3 years without GUS treatment, with the last injection at W52 or 60, for patients who received GUS q16w and q8w, respectively, during part 2 of GUIDE.
GUS=guselkumab, **OC**=observed cases, **PASI**=Psoriasis Area and Severity Index, **SRe**=super responder, **W**=week.

The 13 SRes who remained treatment-free for >3 years maintained overall low PASI scores after GUS withdrawal

Absolute PASI scores over time

Patient	PSO disease duration	PART 1: GUS q8w						PART 2: GUS q8w vs q16w					PART 3: GUS Withdrawal											
		W0	W4	W12	W16	W20	W28	W36	W44	W52	W60	W68	W80	W92	W104	W116	W128	W140	W152	W164	W176	W188	W200	W212	W220
1	LDD	12.8	2.4	0.1	0.1	0	0	0	0	1.2	0	0.6	0	0.6	2.4	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.8	2.6	2.7
8	USDD	22.4	10.4	2.9	1.6	0	0	0	0	0	0	0	0.3	1.8	0	0.8	2	0.6	0.4	0	0.8	2.4	-*	1.6	1.6
13	USDD	10.6	4.6	0	0	0	0	0	0	0	0	0	0	0	0	0	3.3	0.8	0.3	0.1	0.1	0.1	0.1	0.1	1.2
2	ISDD	13.8	7.8	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0
5	USDD	11.8	9.8	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6	0	0	0	0	0
6	USDD	16.2	4.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.2	0	0	0	0
7	USDD	13.8	13.4	7.7	1.7	0	0	0	0	0	0	0	0	1.2	0	0.8	0	0	0	0	0.8	0.4	0	0	0
9	USDD	12.6	3.9	1	0.3	0	0	0	0	0	0	0	1.6	0	0	0.4	0	0	0	0	0	0	0	0	0
10	USDD	12.8	12.8	2	0	0	0	0	0.2	0.1	0.2	0.2	0	0.1	0	0.8	0.1	0	0	0	-*	0	0	0	0
11	USDD	19.6	1.2	1.2	0	0	0	0	0.6	0.6	0	0	4.8	0.6	0	0	0	0	0	0	0	0.6	0	0	0
12	USDD	11.5	0	0	0	0	0	0	0	0	0	0	0	0	1.6	0	0	0	0	0	0	0.6	0.2	0	0
3	USDD	13	10	3.6	2.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4	USDD	18.6	2.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

71% of all PASI assessments showed complete skin clearance

This material is distributed for scientific purposes only by Medical Connect and is not for promotional use

*Visit was remote. Red: PASI≥10, yellow: ≥3<10, light green: >0-<3, dark green: PASI=0. **GUS**=guselkumab, **ISDD**=intermediate-short disease duration, **LDD**=long disease duration, **PASI**=Psoriasis Area and Severity Index, **PSO**=psoriasis, **q8w**=every 8 weeks, **q16w**=every 16 weeks, **SRe**=super responder, **USDD**=ultra-short disease duration, **W**=week.

In all, 3 SRes maintained low PASI scores with minor fluctuations after GUS withdrawal, showing no consistent pattern of increase over time

Absolute PASI scores over time

Patient	PSO disease duration	PART 1: GUS q8w						PART 2: GUS q8w vs q16w					PART 3: GUS Withdrawal											
		W0	W4	W12	W16	W20	W28	W36	W44	W52	W60	W68	W80	W92	W104	W116	W128	W140	W152	W164	W176	W188	W200	W212	W220
1	LDD	12.8	2.4	0.1	0.1	0	0	0	0	1.2	0	0.6	0	0.6	2.4	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.8	2.6	2.7
8	USDD	22.4	10.4	2.9	1.6	0	0	0	0	0	0	0	0.3	1.8	0	0.8	2	0.6	0.4	0	0.8	2.4	-*	1.6	1.6
13	USDD	10.6	4.6	0	0	0	0	0	0	0	0	0	0	0	0	0	3.3	0.8	0.3	0.1	0.1	0.1	0.1	0.1	1.2
2	ISDD	13.8	7.8	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0
5	USDD	11.8	9.8	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6	0	0	0	0	0
6	USDD	16.2	4.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.2	0	0	0	0
7	USDD	13.8	13.4	7.7	1.7	0	0	0	0	0	0	0	0	1.2	0	0.8	0	0	0	0	0.8	0.4	0	0	0
9	USDD	12.6	3.9	1	0.3	0	0	0	0	0	0	0	1.6	0	0	0.4	0	0	0	0	0	0	0	0	0
10	USDD	12.8	12.8	2	0	0	0	0	0.2	0.1	0.2	0.2	0	0.1	0	0.8	0.1	0	0	0	-*	0	0	0	0
11	USDD	19.6	1.2	1.2	0	0	0	0	0.6	0.1	0	0	4.8	0.6	0	0	0	0	0	0	0	0.6	0	0	0
12	USDD	11.5	0	0	0	0	0	0	0	0	0	0	0	0	1.6	0	0	0	0	0	0	0.6	0.2	0	0
3	USDD	13	10	3.6	2.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4	USDD	18.6	2.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

This material is distributed for scientific purposes on J&J Medical Connect and is not for promotional use

*Visit was remote. Red: PASI≥10, yellow: ≥3<10, light green: >0-<3, dark green: PASI=0. **GUS**=guselkumab, **ISDD**=intermediate-short disease duration, **LDD**=long disease duration, **PASI**=Psoriasis Area and Severity Index, **PSO**=psoriasis, **q8w**=every 8 weeks, **q16w**=every 16 weeks, **SRe**=super responder, **USDD**=ultra-short disease duration, **W**=week.

A total of 8 SRes experienced isolated increases in PASI scores, re-achieving PASI = 0 at follow-up visits without the need for re-treatment

Absolute PASI scores over time

Patient	PSO disease duration	PART 1: GUS q8w						PART 2: GUS q8w vs q16w					PART 3: GUS Withdrawal											
		W0	W4	W12	W16	W20	W28	W36	W44	W52	W60	W68	W80	W92	W104	W116	W128	W140	W152	W164	W176	W188	W200	W212	W220
1	LDD	12.8	2.4	0.1	0.1	0	0	0	0	1.2	0	0.6	0	0.6	2.4	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.8	2.6	2.7
8	USDD	22.4	10.4	2.9	1.6	0	0	0	0	0	0	0	0.3	1.8		0.8	2	0.6	0.4	0	0.8	2.4	-*	1.6	1.6
13	USDD	10.6	4.6	0	0	0	0	0	0	0	0	0	0	0	0	0	3.3	0.8	0.3	0.1	0.1	0.1	0.1	0.1	1.2
2	ISDD	13.8	7.8	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0
5	USDD	11.8	9.8	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6	0	0	0	0	0
6	USDD	16.2	4.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.2	0	0	0	0
7	USDD	13.8	13.4	7.7	1.7	0	0	0	0	0	0	0	0	1.2	0	0.8	0	0	0	0	0.8	0.4	0	0	0
9	USDD	12.6	3.9	1	0.3	0	0	0	0	0	0	0	1.6	0	0	0.4	0	0	0	0	0	0	0	0	0
10	USDD	12.8	12.8	2	0	0	0	0	0.2	0.1	0.2	0.2	0	0.1	0	0.8	0.1	0	0	0	-*	0	0	0	0
11	USDD	19.6	1.2	1.2	0	0	0	0	0.6	0.6	0	0	4.8	0.6	0	0	0	0	0	0	0	0.6	0	0	0
12	USDD	11.5	0	0	0	0	0	0	0	0	0	0	0	0	1.6	0	0	0	0	0	0	0.6	0.2	0	0
3	USDD	13	10	3.6	2.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4	USDD	18.6	2.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

This material is distributed for scientific purposes on the Medical Connect and is not for promotional use

*Visit was remote. Red: PASI≥10, yellow: ≥3<10, light green: >0-<3, dark green: PASI=0. **GUS**=guselkumab, **ISDD**=intermediate-short disease duration, **LDD**=long disease duration, **PASI**=Psoriasis Area and Severity Index, **PSO**=psoriasis, **q8w**=every 8 weeks, **q16w**=every 16 weeks, **SRe**=super responder, **USDD**=ultra-short disease duration, **W**=week.

In all, 2 SRes, both with USDD (<15 months), achieved complete skin clearance at all visits for >3 years after GUS withdrawal

Absolute PASI scores over time

Patient	PSO disease duration	PART 1: GUS q8w						PART 2: GUS q8w vs q16w					PART 3: GUS Withdrawal											
		W0	W4	W12	W16	W20	W28	W36	W44	W52	W60	W68	W80	W92	W104	W116	W128	W140	W152	W164	W176	W188	W200	W212	W220
1	LDD	12.8	2.4	0.1	0.1	0	0	0	0	1.2	0	0.6	0	0.6	2.4	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.8	2.6	2.7
8	USDD	22.4	10.4	2.9	1.6	0	0	0	0	0	0	0	0.3	1.8		0.8	2	0.6	0.4	0	0.8	2.4	-*	1.6	1.6
13	USDD	10.6	4.6	0	0	0	0	0	0	0	0	0	0	0	0	0	3.3	0.8	0.3	0.1	0.1	0.1	0.1	0.1	1.2
2	ISDD	13.8	7.8	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0
5	USDD	11.8	9.8	0.6	0	0	0	0	0	0	0	0		0	0	0	0	0	0	0.6	0	0	0	0	0
6	USDD	16.2	4.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.2	0	0	0	0
7	USDD	13.8	13.4	7.7	1.7	0	0	0	0	0	0	0	0	1.2	0	0.8	0	0	0	0	0.8	0.4	0	0	0
9	USDD	12.6	3.9	1	0.3	0	0	0	0	0	0	0	1.6	0	0	0.4	0	0	0	0	0	0	0	0	0
10	USDD	12.8	12.8	2	0	0	0	0	0.2	0.1	0.2	0.2	0	0.1	0	0.8	0.1	0	0	0	-*	0	0	0	0
11	USDD	19.6	1.2	1.2	0	0	0	0	0.6		0	0	4.8	0.6	0	0	0	0	0	0	0	0.6	0	0	0
12	USDD	11.5	0	0	0	0	0	0	0	0	0	0	0	0	1.6	0	0	0	0	0	0	0.6	0.2	0	0
3	USDD	13	10	3.6	2.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4	USDD	18.6	2.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

This material is distributed for scientific purposes on J&J Medical Connect and is not for promotional use

Both patients achieved complete skin clearance as of W20 with GUS q8w in part 1 of the study

*Visit was remote. Red: PASI≥10, yellow: ≥3<10, light green: >0-<3, dark green: PASI=0. **GUS**=guselkumab, **ISDD**=intermediate-short disease duration, **LDD**=long disease duration, **PASI**=Psoriasis Area and Severity Index, **PSO**=psoriasis, **q8w**=every 8 weeks, **q16w**=every 16 weeks, **SRe**=super responder, **USDD**=ultra-short disease duration, **W**=week.

Key Takeaways

GUIDE is the **first prospective large scale RCT to identify and characterize** patients with moderate-to-severe PSO who **maintained disease control for >3 years** after PSO treatment withdrawal

- ✓ **13 SRes maintained disease control for >3 years after GUS withdrawal,** with substantially lower disease activity throughout the withdrawal period than before GUS treatment was initiated
- ✓ SRes initiating **GUS within 15 months of disease onset** had a significantly **higher likelihood of remaining treatment-free** compared to those with longer disease duration
  - ✓ 11 of 13 SRes who maintained treatment-free status had USDD
  - ✓ 2 SRes, both with USDD, showed complete skin clearance at all visits for >3 years
  - ✓ ~1 in 6 SRes with USDD who initiated withdrawal, maintained treatment-free status for >3 years
- ✓ Overall PASI scores remained low during withdrawal, with a **majority of all assessments showing complete skin clearance**

Together with previous biomarker data[1-3], these findings suggest that **GUS may have disease-modifying properties in a subset of patients**, particularly those initiating treatment early in the disease course. The potential for disease modification with guselkumab treatment should be further explored.

This material is distributed for scientific purposes only to J&J Medical Contact, and is not for promotional use

1. Eyerich K *et al. JAMA Dermatol* 2024;e242463. **2.** Angsana J *et al.* Poster presentation at: ISDS Congress; 15–18 November 2023; Vienna, Austria. P180. **3.** Angsana J *et al.* Oral presentation at: ISID Congress; 10–13 May 2023; Tokyo, Japan. Presentation 587. **GUS**=guselkumab, **PASI**=Psoriasis Area and Severity Index, **PSO**=psoriasis, **RCT**=randomized controlled trial, **SRe**=super responder, **USDD**=ultra-short disease duration.

Acknowledgements

- We give our thanks to all GUIDE patients, investigators, nurses and study coordinators who made this study possible

- In Memoriam: Dr. Maurizio Podda. As we conclude this work on the GUIDE study, we would like to take a moment to honor and remember our esteemed colleague, Dr. Maurizio Podda

- Medical writing support was provided by Joanna Dembowy, PhD of JSS Medical Research, under the direction of the authors in accordance with Good Publication Practice guidelines (*Ann Intern Med* 2022;175:1298–304)

- Sponsored by Johnson & Johnson

This material is distributed for scientific purposes on J&J Medical Connect, and is not for promotional use

SRes with SDD (≤2 years) were 50% more likely to remain treatment-free vs SRes with LDD (<2 years) through 3 years after GUS withdrawal



Number at risk

LDD	135	135	120	70	39	24	13	8	5	5	3	3	2	2
SDD	138	138	132	109	76	50	35	28	23	22	19	15	14	12

Disease duration	Years
SDD	≤2
LDD	>2

Median treatment-free duration

SDD patients: 378 days
LDD patients: 259 days

SDD vs LDD: ↑ 119 days (+46%)

This material is distributed for scientific purposes on J&J Medical Connect, and is not for promotional use

CI=confidence interval, **GUS**=guselkumab, **HR**=hazard ratio, **LDD**=long disease duration, **PSO**=psoriasis, **SDD**=short disease duration, **SRe**=super responder.

SRes with SDD (≤2 years) vs LDD (>2 years) had a higher probability of remaining treatment-free following withdrawal from GUS q8w dosing



Number at risk

LDD	69	69	62	32	18	12	6	4	3	3	1	1	0	0
SDD	67	67	63	49	37	22	18	14	11	11	10	10	9	7

Disease duration	Years
SDD	≤2
LDD	>2

Median treatment-free duration

SDD patients: 398 days
LDD patients: 233 days

SDD vs LDD:
↑ 165 days (+71%)

This material is distributed for scientific purposes on J&J Medical Connect, and is not for promotional use

CI=confidence interval, **GUS**=guselkumab, **HR**=hazard ratio, **LDD**=long disease duration, **PSO**=psoriasis, **q8w**=every 8 weeks, **SDD**=short disease duration, **SRe**=super responder.